Our Clinical Staff

We've assembled one of the leading teams of MS specialists in the world right here at the RMMSC at CU. Each of our neurologists spends time treating patients, conducting research in their particular interest areas, and teaching the next generation of MS specialty physicians at the University of Colorado School of Medicine. For appointment information, please call the RMMSC at CU today at 720-848-2080 x. 4.

Dr. Robert Gross

robert grossDr. Robert Gross attended college at Columbia University and medical school at NYU School of Medicine. He completed Internship in Internal Medicine and Residency in Adult Neurology at Brown University in Providence. He then returned to New York to complete a fellowship in Multiple Sclerosis/Neuroimmunology at the CGD Center for MS at Mount Sinai Hospital.  Dr. Gross sees patients with MS and related disorders of the central nervous system. He divides his time between patient care, teaching, and clinical research. Research interests include the identification of biomarkers associated with treatment response in MS and the establishment of prospective databases to aid in prognostication. He recently moved to Colorado with his wife and beagle/terrier puppy and is thrilled to be living out West for the first time.


Dr. Amanda Piquet

Assistant Professor of Neurology
CU School of Medicine

Piquet Amanda cudocsDr. Piquet is a graduate of Penn State University School of Medicine and completed her neurology residency at Harvard’s Neurology Program at Massachusetts General Hospital and Brigham and Women’s Hospital. She completed a Neuroimmunology/Autoimmune Neurology Fellowship at the University of Utah. Dr. Piquet sees patients with autoimmune neurological diseases, multiple sclerosis and other inflammatory diseases of the central nervous system. Her main clinical interest includes antibody-mediated disorders of the nervous system such as autoimmune encephalitis and stiff-person syndrome as well as demyelinating disease including multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD). She has additional expertise in other inflammatory diseases including neurosarcoidosis, vasculitis, and central nervous system complications of rheumatological diseases such as lupus and Sjögren syndrome, among others. 

Dr. Piquet’s research interests include optimizing diagnosis and treatment for patients with autoimmune neurological diseases; this includes the development of standardized guidelines and protocols for the diagnostic work up and treatment for autoimmune encephalitis. She is also interested in the identification of biomarkers associated with autoimmune neurological disease.

Dr. Timothy Vollmer

Medical Director, RMMSC
Co-Director, RMMSC at University of Colorado
Professor and Vice Chair of Clinical Research, CU School of Medicine, Department of Neurology

VollmerDr. Vollmer is a graduate of Stanford University School of Medicine and a former faculty member at the Yale School of Medicine. He is Director of Neuroscience Clinical Research at the University of Colorado Anschutz Medical Campus, the Medical Director of the RMMSC and Co-Director of the RMMSC at University of Colorado.
Dr. Vollmer has participated in more than 100 clinical studies in MS and is currently the principal investigator on 13 funded studies. Although he is involved with many different clinical studies and consults on many others, his current areas of interest are focused in three areas. The first is related to developing an understanding of the biology behind neurological reserve and how neurological reserve can be used to help patients recover and maintain function. The second relates to the loss of neurons in MS. Damage to neurons is the major cause of disability in MS but exactly what leads to their death and how current therapies impact this are not known. Finally, although there are many therapies for MS, there is no cure currently in human trials. Dr. Vollmer is pursuing an approach to treating MS (and possibly young people at risk of MS) similar to a vaccine. This research continues, hopefully in preparation for a human trial. Dr. Vollmer is an ex officio member of the RMMSC Board of Directors.

Dr. John Corboy

Co-Director, RMMSC at University of Colorado
Professor and Director of Faculty Affairs, CU School of Medicine, Department of Neurology

dr john corboy

Dr. Corboy is a graduate of University of Pennsylvania and did his neurology residency there, with a fellowship at Johns Hopkins University in Baltimore. He specialized in MS and neurovirology at the University of Minnesota Medical Center before coming to Colorado in 1994. In 1997, he founded the University of Colorado Multiple Sclerosis Center, now transformed into the Rocky Mountain Multiple Sclerosis Center at University of Colorado, a multidisciplinary group offering state-of-the-art care and research to multiple sclerosis patients. Dr. Corboy is Co-Director of the RMMSC at CU, and also the founding editor of Neurology: Clinical Practice, the clinical journal of the American Academy of Neurology.

Dr. Corboy’s research interests and projects include novel therapeutics for MS, treatment decisions in MS care, understanding how long to use conventional DMT's, and defining risk factors for development of MS. He is the director of the RMMSC Tissue Bank, which delivers autopsied brain and other tissues to researchers throughout the world. He has been on the board of the Colorado-Wyoming chapter of the National MS Society for
more than a decade.

Dr. Corboy also provides regular MS specialty care to patients at the Denver VA Medical Center.

Dr. Jeffrey Bennett

Professor of Neurology and Ophthalmology,
CU School of Medicine, Department of Neurology

BennettDr. Bennett received his Biochemistry and Philosophy Degrees at Case Western Reserve University. He then received his medical and doctoral degrees at Stanford University. Dr. Bennett directs research programs on optic neuritis, demyelinating disorders, and ocular inflammatory diseases. He also maintains active specialty practices in neuro-ophthalmology, multiple sclerosis, neuromyelitis optica, and neuroimmunology.

As a clinician-scientist, Dr. Bennett is devoted to understanding the effects of autoimmune demyelination on the nervous system and using this knowledge to transform the care of affected individuals. In the clinic, Dr. Bennett directs clinical trials on new therapies for optic neuritis and neuromyelitis optica. In the laboratory, Dr. Bennett is working to identify the targets of the immune response in neuromyelitis optica and multiple sclerosis and is working to understand the mechanisms by which these disorders cause damage to the nervous system. His laboratory uses multiple experimental methods to evaluate the targets and action of antibodies derived from immune cells in the spinal fluid of neuromyelitis optica and multiple sclerosis patients, and employs state-of-the art techniques to establish the role of these antibodies in causing disease. Through his work, he has developed a novel antigen-specific therapy for neuromyelitis optica and is working towards similar goals in multiple sclerosis.